FindTrial
Sign In

UAE Inhibitor TAK-243

DRUG2 trials

Sponsors

National Cancer Institute (NCI)

Conditions

Advanced LymphomaAdvanced Malignant Solid NeoplasmIndolent Non-Hodgkin LymphomaMetastatic Malignant Solid NeoplasmMyelodysplastic Syndrome With Excess BlastsRecurrent Acute Myeloid LeukemiaRecurrent Malignant Solid NeoplasmRecurrent Myelodysplastic Syndrome

Phase 1

TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts
Active, not recruitingNCT03816319
National Cancer Institute (NCI)Myelodysplastic Syndrome With Excess Blasts, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome +4
Start: 2025-03-12End: 2026-10-24Target: 42Updated: 2026-09-16
Studying TAK-243 in Patients With Advanced Cancer
RecruitingNCT06223542
National Cancer Institute (NCI)Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Indolent Non-Hodgkin Lymphoma +3
Start: 2025-03-24End: 2027-04-15Target: 95Updated: 2026-05-13